Rossari Biotech Q3 FY26 Results: Revenue Grows 13% to ₹581.7 Crores, Board Approves Saudi Arabia Expansion

Rossari Biotech Limited announced its financial results for Q3 FY26, demonstrating steady growth across key performance metrics despite a softer domestic demand environment. The specialty chemicals manufacturer reported consolidated revenue of ₹581.7 crores for the quarter ended December 31, 2025, representing a 13% year-on-year increase from ₹512.7 crores in the corresponding period last year.

Financial Performance Overview

The company's Q3 FY26 performance showed consistent growth across major financial parameters:

Metric	Q3 FY26	Q3 FY25	Growth (%)
Revenue from Operations	₹581.7 cr	₹512.7 cr	+13%
EBITDA	₹68.9 cr	₹64.8 cr	+6%
EBITDA Margin	11.8%	12.6%	-80 bps
PAT	₹32.8 cr	₹31.7 cr	+3%
EPS (Diluted)	₹5.90	₹5.70	+3.5%

EBITDA improved by 6% to ₹68.9 crores from ₹64.8 crores, though the EBITDA margin compressed to 11.8% from 12.6% in the previous year. Profit After Tax (PAT) increased by 3% to ₹32.8 crores from ₹31.7 crores, while diluted earnings per share stood at ₹5.90 compared to ₹5.70 in Q3 FY25.

Nine-Month Performance Highlights

For the nine-month period ending December 31, 2025, Rossari Biotech maintained strong momentum:

Parameter	9M FY26	9M FY25	Change (%)
Revenue from Operations	₹1,711.5 cr	₹1,500.7 cr	+14%
EBITDA	₹208.7 cr	₹195.6 cr	+7%
EBITDA Margin	12.2%	13.0%	-80 bps
PAT	₹103.2 cr	₹101.9 cr	+1%
EPS (Diluted)	₹18.60	₹18.40	+1.1%

Revenue from operations reached ₹1,711.5 crores, marking a 14% increase from ₹1,500.7 crores in 9M FY25. EBITDA grew 7% to ₹208.7 crores, while PAT improved marginally by 1% to ₹103.2 crores.

Segment-wise Growth Performance

The company achieved balanced growth across its diversified business portfolio during Q3 FY26:

Home, Personal Care and Performance Chemicals (HPPC): Recorded 11% YoY growth, reflecting stable demand despite softer domestic conditions
Textile Specialty Chemicals (TSC): Delivered robust 18% YoY growth
Animal Health and Nutrition (AHN): Achieved strong 39% YoY growth

This diversified performance across segments helped offset moderation in select end-markets, while exports continued to support overall performance through focused efforts to deepen relationships in key geographies and expand the customer base.

Strategic Expansion Initiative

The Board of Directors has granted in-principle approval for establishing greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA). Key aspects of this strategic initiative include:

Development Aspect	Details
Implementation Entity	Rossari International Limited Company (wholly-owned subsidiary)
Strategic Objective	Enhance supply chain resilience and accelerate speed-to-market
Funding Approach	Equity, debt, internal accruals, or combination thereof
Current Status	Subject to customary evaluations and regulatory approvals

The project aims to strengthen the company's position as a major player in specialty chemicals manufacturing while exploring available regional incentives and evaluating optimal funding options.

Management Commentary

Executive Chairman Edward Menezes and Managing Director Sunil Chari highlighted the company's resilient performance amid challenging market conditions. They emphasized that profitability was impacted by ongoing investments in capacity expansion, product development, and market-seeding initiatives, which are intended to strengthen long-term competitive positioning. The management expressed confidence that operating leverage, scale benefits, and an improving product mix will support margin improvement over time, with the phased capacity expansion program across verticals continuing to progress well.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.86%	-7.17%	-8.66%	-28.63%	-35.63%	-38.50%

Rossari Biotech Limited has officially announced an earnings conference call to discuss its Q3 FY26 financial performance with investors and analysts. The company filed this intimation with stock exchanges under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The earnings conference call has been scheduled with specific parameters for participant access:

Parameter:	Details
Date:	Monday, January 19, 2026
Time:	4:00 PM IST
Meeting Type:	Conference Call - Group Meet (Telecommunication)
Participants:	Investors and Analyst Groups
Universal Dial-in:	+91 22 6280 1141 / 7115 8042

Meeting Structure and Agenda

The conference call will follow a structured format designed to provide comprehensive insights into the company's quarterly performance. The session will commence with a brief management discussion covering financial results for the quarter and nine months ended December 31, 2025. Following the management presentation, an interactive Question & Answer session will allow participants to engage directly with the senior management team.

Pre-Registration and Access

To enhance participant experience, Rossari Biotech has arranged for zero wait time access through pre-registration. Participants can register in advance using the provided DiamondPass system, eliminating the need to wait for operator assistance when joining the call.

Company Background

Rossari Biotech Limited operates as a specialty chemicals manufacturer, providing intelligent and sustainable solutions across multiple industries. The Mumbai-headquartered company maintains strategically located manufacturing facilities at Silvassa and Dahej. The company's product portfolio spans Home, Personal Care and Performance chemicals (HPPC), Textile specialty chemicals, and Animal Health and Nutrition (AHN) segments.

Regulatory Compliance

The earnings call announcement was signed by Parul Gupta, Head - Company Secretary & Legal (Membership No.: A38895), and submitted to both BSE Limited and National Stock Exchange of India Limited on January 13, 2026. This filing ensures compliance with mandatory disclosure requirements for listed companies regarding investor communication activities.